• GEMXX Corporation is a Las Vegas-based jewelry maker developing its strategic gold metal and ammolite gemstone from a unique mine-to-market product pipeline
• Gold has enjoyed record high prices during a “roaring 2023” run, and price fluctuations surrounding those highs have failed to deter optimism that demand for the precious metal may remain during the coming year
• GEMXX is the only publicly traded ammolite gemstone company in the world, and plans to expand its gemstone and jewelry production by 300 percent next year
• The company reported upbeat earnings and no long-term debt in its recent Q2 financial statement

With the close of its 2023 mining test season, mine-to-market jewelry enterprise GEMXX (OTC: GEMZ) is celebrating positive outcomes from its mine assessment, debt management practices, and revenue operations, as it prepares for further growth in 2024. GEMXX reported upbeat earnings during its Q2 statement published Nov. 21, stating that its account receivables rose from $701,252 to $1.3 million YOY, total assets increased to $20.1 million, and net income grew from $132,842 to $212,526 — all while maintaining no long-term debt (https://ibn.fm/QOuV2). The company is led by an executive team with over 160 years of combined experience in the market, and gold’s continued demand strength has provided GEMXX’s leadership with encouragement as it pursues its long-term strategy.

The company is planning to expand its ammolite gemstone and jewelry production by 300 percent next year, with expectations of supplying $5.5 million worth of ammolite jewelry through GEMXX’s shopping channel division. The ammolite gems are derived from the fossilized shells of ammonites, a group of large, extinct marine nautiluses, and are prized for their iridescent coloration. Alberta is the only place the gemstones are commercially mined, and world-class gem cutters help GEMXX turn them into the distinctive jewelry for which it is becoming known.

GEMXX, unique in that the company draws on its own mining assets for the gold and ammolite gemstones it uses in colorful jewelry, is the only publicly traded ammolite gemstone company in the world, and lately has been exploring the potential of its gold resources as well.

The World Gold Council (“WGC”) continues to remain optimistic about the precious metal’s performance regardless of price fluctuations surrounding recent record highs.

“Heightened geopolitical tensions in a key election year for many major economies, combined with continued central bank buying could provide additional support for gold,” the WGC stated in its Gold Outlook 2024 report published earlier this month (https://ibn.fm/7s2nL).

“There’s no fiscal discipline in the United States. People have gotten used to free money. It’s going to be hard to tighten things up,” giant gold producer Barrick Gold Corp. CEO Mark Bristow added in a recent interview with the Financial Post (https://ibn.fm/7KkE1). “Overall, I feel gold has much more upside than downside risk looking forward.”

The company processed 31,200 cubic yards of gold-bearing ore yielding 0.929 ounces per 100 cubic yards at its 498-acre Snow Creek gold property in 2023 and expects to triple production at the site during the coming year, according to a separate Nov. 7 report (https://ibn.fm/uZgfK). Between Snow Creek and the company’s second British Columbia gold property, the Rosella Creek mine, GEMXX reports estimated production potential of over 100,000 ounces of easily recoverable gold (https://ibn.fm/b9nQn). GEMXX is working to acquire a third gold property with an estimated 2.2 million to 4 million ounces of recoverable gold.

GEMXX’s control over each stage of its production — from mining to processing the product and further to manufacturing end-product jewelry then worldwide distribution — gives the company a distinct competitive advantage over other players in the precious metals sector.

Those interested in participating through Reg A financing are encouraged to visit the company’s investor page (https://ibn.fm/u1Sd0) or contact company officials for more information (ir@gemxx.com – 702-930-1815).

For more information, visit the company’s website at www.GEMXX.com/investors.

NOTE TO INVESTORS: The latest news and updates relating to GEMZ are available in the company’s newsroom at https://ibn.fm/GEMZ

• SOHM is launching a line of 13 new chewables that offer a range of health benefits and expand the company’s preventative care product portfolio
• The new line will be available online through Amazon.com and the company’s direct-to-consumer website and will be showcased at industry conferences in 2024
• SOHM is addressing its increased product demand by establishing a new CDMO GMP manufacturing facility in Carlsbad, California
• The new manufacturing facility is expected to be open by the end of 2023, and shareholders will be updated about its operations during its year-end 2023 report

SOHM (OTC: SHMN), a pharmaceutical, nutraceutical, and cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories, recently announced the launch of new products to the company’s catalog and expansion into a new CDMO GMP manufacturing facility in Carlsbad, California.

SOHM is set to enter the global vitamin gummies market by launching 13 new SOHM Nutrients Brand Chewables. The global vitamins market, valued at $6.84 billion in 2022, is expected to reach $18.76 billion by 2031, driven by increased consumer spending on healthcare and self-care products, health benefits, appealing flavors, convenience, and easy accessibility (https://ibn.fm/96fvb).

The suite of SOHM Nutrients’ Brand Chewables offers a range of health benefits, individually wrapped single servings for convenience, a chewable format that requires no water, and delicious flavors like mango, strawberry, pineapple, and toffee (https://ibn.fm/58luQ). These products are vegan-friendly and free from nuts, gluten, gelatin, and soy. Dr. David Aguilar, COO of SOHM, emphasized its commitment to expanding its preventive care product portfolio and announced plans for additional product launches in 2024.

The new chewables will be available for retail purchase on Amazon.com and the company’s Direct-to-Consumer website, priced competitively with top-selling gummies. SOHM also plans to showcase these products at industry conferences in 2024, with conference schedules pending finalization.

SOHM has unveiled plans to address increasing product demand by establishing a new facility in Carlsbad, California (https://ibn.fm/1VB5C). This strategic move is driven by the need to meet existing and anticipated orders while the company’s primary facility in downtown San Diego undergoes renovations to optimize operations. SOHM is on track to complete the engineering batches produced at the San Diego facility by Q1 2024, aligning with its mission to enhance production capacity and efficiency.

The new Carlsbad facility provides ample space to accommodate the manufacturing of topical products and SOHM’s overall operations, with an additional 2,500 square feet allocated for storing finished products. Initial operations at the Carlsbad facility will have a daily capacity of 500 gallons (1,892 liters) and focus on topical products. However, plans are in place to expand its capabilities to include soft-gel suppositories by the end of Q1 2024 or the beginning of Q2 2024.

The Carlsbad facility is nearing completion, expecting to achieve full cGMP manufacturing capacity by December 2023. This expansion comes at an opportune time as the bio and pharma Contract Development and Manufacturing Organization (“CDMO”) market has reached a value of $223 billion in 2023 and is projected to grow to $309 billion by 2028, reflecting a 6.74% Compound Annual Growth Rate (“CAGR”) between 2018 and 2028 (https://ibn.fm/352dR).

The company’s management anticipates sharing further updates on the Carlsbad facility in its year-end 2023 report and expresses gratitude for its stakeholders’ continued support and trust. This expansion signifies SOHM’s commitment to meeting market demands and facilitating growth in the pharmaceutical manufacturing sector.

For more information, visit the company’s website at www.SOHM.com.

NOTE TO INVESTORS: The latest news and updates relating to SHMN are available in the company’s newsroom at https://ibn.fm/SHMN

• SuperCom recently secured a new contract to deploy its cutting-edge solutions as part of its broader plan to enhance public safety and support rehabilitation efforts in communities across Kentucky
• The contract reaffirms the company’s commitment to innovation and excellence in the field of electronic monitoring, according to Ordan Trabelsi, SuperCom’s CEO and President
• It also marks another valuable step in the company’s expansion within the U.S.
• The contract allows the company to bring its advanced technology to more communities and aid in the crucial work of domestic violence prevention and offender monitoring

SuperCom (NASDAQ: SPCB), a leading global provider of advanced safety, identification, connectivity, and security products and solutions to governments as well as public and private organizations around the world, recently secured a new contract with a Kentucky-based prominent service provider of electronic monitoring (“EM”) products and services. Under this new contract, SuperCom will deploy its newest proprietary technologies, namely the new PureOne GPS bracelet and the PureProtect for domestic violence protection (https://ibn.fm/TZeXu).

“We are proud to see our new proprietary solutions gaining traction in new regions in the U.S., reaffirming our commitment to innovation and excellence in the field of electronic monitoring. This new contract allows us to bring our advanced technology to more communities and aid in the crucial work of domestic violence prevention and offender monitoring. It is a testament to the hard work of our team and the trust our partners place in our technology,” said SuperCom CEO and President Ordan Trabelsi.

The PureOne monitoring solution is an all-in-one device that contains Global Navigation Satellite Systems (“GNSS”), LTE cellular, and radio-frequency (“RF”) Bluetooth low energy (“BLE”) modules. The integrated BLE module enables the device to communicate with the PureBeacon, a secure RF device that provides surveillance of offenders when GPS is not suitable or available. On the other hand, the GNSS module relies on satellites to provide geo-positioning data, while the cellular module facilitates communication with PureMonitor. SuperCom’s PureMonitor is cloud-based software that remotely monitors the PureOne device and its user, sends alerts, creates reports, and performs analytics.

PureProtect is a smartphone application that supports GNSS, Wi-Fi location, and location-based service (“LBS”) tracking, as well as LTE and 5G cellular communication. It can send GNSS and RF proximity range alerts and displays an on-screen map that shows the aggressor’s and victim’s location. It also has an SOS emergency panic button that victims can use in case of immediate danger. Thanks to these features and capabilities, the PureProtect app links SuperCom’s disparate domestic violence solutions – the PureOne bracelet and the PureMonitor software – offering a protective front line for victims of domestic violence.

SuperCom’s move to deploy these cutting-edge solutions as part of the new contract aligns with its broader plan to enhance public safety and support rehabilitation efforts in communities across Kentucky. It also marks another valuable step in the company’s expansion within the U.S., given that SuperCom has previously signed EM contracts in Idaho, California, and Texas. The new contract builds on the company’s continued success in delivering high-quality services and cutting-edge monitoring solutions within and across state borders.

“Our commitment to improving public safety and supporting rehabilitation efforts is at the core of our mission. Leveraging our growing customer base and technology expertise, we plan to continue developing and providing advanced solutions that meet the evolving needs in our industry and help enhance public safety worldwide,” concluded Trabelsi.

For more information, visit the company’s website at www.SuperCom.com.

NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB

The Talent Acquisition Week By GSMI is hosting three phenomenal events this week namely the Social Recruiting Strategies Conference, the Talent Sourcing Strategies Summit, and the Employer Branding Strategies Conference, in San Diego. Sourcers, recruiters, talent branders, HR managers & TA leaders, across industry verticals, are all invited to attend this comprehensive event connecting all recruiting sectors on the global spectrum. 

These events will feature panel discussions, case studies, and practitioner-to-practitioner sessions that attendees can leverage to gain in-depth knowledge about the latest recruiting industry trends, suitable candidates, tools and technology, and more. Learn the intricacies of recruitment marketing and tips to acquire the best industry talents to build a robust team. Attendees can connect and collaborate with the top TA & HR representatives and learn from their professional journeys. 

The Talent Acquisition Week 2024 offers:

• TA professionals can leverage networking opportunities to explore sourcing, employer branding, recruiting, and more
• Get insights, tips, and strategies from fellow TA practitioners for improving recruitment quality and candidate experiences
• Avail actionable tips and suggestions from eminent leaders conducting panel discussions and speaker sessions at the #TA Week 2024
• Learn the best employer branding techniques for building a great work team
• Get the best content tips to upgrade a company’s reputation
• Understanding the best criteria for hiring and sourcing the most suitable candidates

TA leaders and HR pros will host speaker sessions discussing the most vital topics of the recruitment arena and the best methods of recruitment and retention. This event offers the best platform for promising talent to be discovered. TA leaders can provide clear and effective recruitment information to an immersive audience. Fellow participants can develop long-term industry relations and get the best strategies for recruitment from fellow attendees.

To know more, please visit https://ibn.fm/hiA26

• SekurRelay allows business executives to benefit from Sekur’s privacy and security features seamlessly using their existing email while the rest of the employees maintain their existing hosting provider
• The service provides extra protection to senior employees and government officials against Business Email Compromise attacks
• Sekur plans to offer SekurRelay worldwide through telecom partners like America Movil in Latin America and new partners in the Middle East

Sekur Private Data (CSE: SKUR) (OTCQB: SWISF) (FRA: GTD0), a cybersecurity and internet privacy provider of Swiss-hosted solutions for secure and private communications, recently announced the launch of its SekurRelay Enterprise Email Solution. This new addition to Sekur’s existing suite of products allows corporate executives and management to “split” their company email domain in two without migrating the entire company of employees – eliminating a huge roadblock to mass adoption of SekurMail by large corporations and government entities (https://ibn.fm/xysyN).

SekurRelay simplifies the process for company employees to seamlessly transition their current business email to Sekur’s secure and private email platform while maintaining their existing business email domain, such as @company.com. This innovative solution eliminates the need for enterprise IT departments to undertake the complex and costly task of migrating their entire workforce to Sekur to maintain a consistent domain email address.

With SekurRelay, employees can continue using their current provider and email addresses like @company.com, while company executives and managers can enjoy the benefits of SekurMail with their existing email addresses. This “Inbound Relay” effectively addresses a significant challenge, as many larger enterprises have hesitated to migrate thousands of employee emails due to the associated complexities and expenses. With SekurRelay, companies of all sizes can safeguard the emails of C-level and management personnel from Business Email Compromise (“BEC”) attacks, all while allowing other employees to stay on their current email hosting providers.

All employee emails will pass through SekurRelay, benefiting from Sekur’s robust malware detection and spam filters, offering an extra layer of protection for everyone, regardless of whether they use SekurRelay. Only SekurRelay account holders will have their emails hosted and delivered through Sekur’s platform.

“We are excited to provide SekurRelay to our customers as it provides protection from BEC attacks to C-level executives and managers who traditionally send highly sensitive emails inside and outside of their organizations,” said Alain Ghiai, CEO of Sekur Private Data. Ghiai further explained that there were several instances when companies wanted to keep their existing email provider for convenience for most of their employees, but wanted to have their C levels use Sekur, while keeping the same company or government domain email.

Sekur can offer the only Swiss-hosted, proprietary, private, and secure communications platform that does not rely on big tech infrastructure, open-source coding, or data mining, therefore exponentially reducing the risk of cyber penetration. “Our prime directive is to provide private and secure communications for everyone, and as we are not connected to any Big Tech platform, we offer a truly independent, private, and secure means of communications, without any data mining, through our proprietary technology and our secure servers based in Switzerland,” Ghiai added.

The feature costs US$200/month per email domain plus an extra US$10/month per email for business accounts using SekurRelay. This totals US$20/month per business email, a minimal expense given SekurMail’s benefits and 100GB storage. For upcoming enterprise accounts in December 2023, the US$200/month domain add-on includes SekurRelay at a lower per-user rate due to a minimum of 50 users per account. SekurMail offers a unique SekurSend/SekurReply feature for secure communication. In 2021, there were 20,000 BEC attacks reported to the FBI.

Sekur plans to offer SekurRelay worldwide through telecom partners like America Movil in Latin America and new partners in the Middle East. This solution streamlines sales to larger businesses, enterprises, and government organizations without disrupting existing IT infrastructure or incurring migration costs, which is crucial in regions with increased cyber threats.

For more information, visit the company’s website at www.SekurPrivateData.com or the company’s product site at www.Sekur.com.

NOTE TO INVESTORS: The latest news and updates relating to SWISF are available in the company’s newsroom at https://ibn.fm/SWISF

• Lexaria, a global innovator in drug delivery platforms, is projected by Zacks SCR to be valued at $10 a share, up from the current $1.50 for 2024
• Zacks SCR projects a 259% YOY revenue growth for 2024 and a 20% growth for 2025, dependent upon the ultimate approval and commercialization of products employing its patented DehydraTECH(TM) technology
• Lexaria also anticipates FDA approval for its IND application and commence its Phase 1b hypertension clinical trial, all in 2024

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has had significant developments in 2023. Most notably, the company has seen more positive results for its patented DehydraTECH(TM) technology for various indications, including potential diabetes treatment, oral nicotine, and hypertension. Results in these studies set the stage for additional clinical trials for 2024. These have contributed to the company’s projected valuation of $10 a share, up from the current $1.50, per a recent Zacks SCR report (https://ibn.fm/g4sZ8).

Zacks SCR projects 259% year-over-year (“YOY”) revenue growth for 2024 and a 20% YOY growth for 2025. This progression will largely depend on the ultimate approval and commercialization of products employing its DehydraTECH technology, mainly since the company receives most of its revenues from licensing and product sales, which can, in part, fund its research and development (“R&D”) operations. The success achieved so far in its hypertension, oral nicotine delivery, and diabetes studies shows important promise, and its management is optimistic that they will be integral to the company’s growth in the coming year.

In addition, other strategic moves that the company has made in 2023 are expected to further contribute to the company’s progress in 2024. Of note is the exclusive global collaboration and license agreement with SulfoSyn Limited that will allow for the non-pharmaceutical use of DehydraTECH with sulforaphane, a chemical compound found in a variety of cruciferous vegetables such as cabbage, cauliflower, and broccoli, among others. It is considered an antioxidant and anti-inflammatory with lots of health benefits. Another is Lexaria’s incorporation of a new wholly-owned subsidiary, Lexaria Nutraceutical Corp., that looks to optimize its DehydraTECH strategy that services several markets that fall under different regulatory regimes worldwide.

Within the first quarter of 2024, Lexaria anticipates approval for their Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) for its planned Phase 1b hypertension clinical trial, using DehydraTECH-CBD. It also hopes to close out its NIC-H22-1 clinical study on nicotine, update on final results, and commence with its Phase 1b hypertension study.  The company’s animal GLP-1 study is also set to begin, with an update on objectives scheduled for the year’s first half.

These initiatives reflect Lexaria’s commitment to creating shareholder value. They also indicate its management’s confidence in its technology. Lexaria has invested a lot of time and resources in the R&D for its technology since 2016, and it is about to pay off. With its unique benefits, which include, but are not limited to, increasing brain absorption, speeding up delivery, and increasing bioavailability, the technology is seeing a decent uptake, and with the plans lined up for 2024, it is bound to be even higher, ultimately stamping Lexaria as a leader in its space.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• SOHM recently acquired ABBIE, a world-class gene-editing platform capable of inserting larger DNA sequences, including full genes, into a desired location of the target cell’s genome
• ABBIE is poised to facilitate drug development, with SOHM confident that its new gene-editing technology can revolutionize the field of cardiology by supporting new ways of discovering and developing drugs
• The ABBIE platform system is easy to operate and boasts high efficiency, low cost, and simple design
• ABBIE improves on some of the shortcomings of CRISPR-Cas9 as well as other gene-editing technologies, such as enabling researchers to edit genes of a large number of cell types at different stages of their life cycles and does not require the cutting of double stranded DNA
• Compared to other gene-editing technologies, ABBIE has achieved significant strides in development with much less R&D spending

Genome editing refers to the modification of a cell’s DNA (genome) to block, improve, restore or add gene expression and gene function. It may be used to modify genomic DNA of a cell or subject to correct or to provide a model for a genetic disease. The process alters the expression of the gene and corrects the mutations or genetic differences that cause disease, thus modulating the disease, for instance. Gene editing is the direct result of advancements in human genomics, clinical medicine, molecular biology, and genetics, which have made it possible to directly target and modify genomic sequences of cells with clearly defined nuclei (eukaryotic cells), including human cells (https://ibn.fm/UHi7v).

Over the years, researchers have developed new gene-editing platforms and technologies, one of which was recently acquired by SOHM (OTC: SHMN), a pharmaceutical, nutraceutical, and cosmeceutical company that manufactures and markets generic drugs. SOHM acquired ABBIE, a world-class gene-editing platform capable of inserting larger DNA sequences, including full genes, into a desired, predetermined, and precise location within the target cell’s genome (https://ibn.fm/ocohf). ABBIE uses non-viral vectors and engineered recombinant proteins combined with targeted integration to insert the DNA sequences.

SOHM’s new gene-editing technology, which is currently undergoing further development to optimize expression and purification of its protein-based platform, can facilitate drug discovery, essentially a process of finding new compounds that can regulate the function of a biological target, such as a gene involved in a disease, RNA, or a protein. SOHM believes ABBIE has the potential to transform and revolutionize the field of cardiology by supporting new ways of discovering and developing pertinent drugs.

According to SOHM COO Dr. David Aguilar, Ph.D., “ABBIE can facilitate drug discovery by allowing researchers to edit the DNA of cells in a dish (in vitro) and make them express a specific gene related to a cardiac disease. For example, ABBIE can be used to create cells that have a mutation in a gene that causes cardiomyopathy, a condition that adversely affects the heart muscle.”

Dr. Aguilar explains that these cells can then be exposed to various therapeutic compounds and subsequently screened to assess the impact such compounds have on the mutated cells as well as the cells’ function. In this way, he holds, ABBIE can help researchers identify new pharmacological candidates that can potentially treat or prevent conditions such as cardiomyopathy.

Moreover, ABBIE can enable researchers to edit the DNA of cells directly in the body (in vivo) and alter their behavior or activity. “For example, ABBIE can be used to target and modify the cardiac conduction cells of the heart, which are responsible for generating and transmitting electrical signals that coordinate the heartbeat. ABBIE can be used to correct or enhance the function of these cells in patients who have genetic conditions that affect their cardiac conduction system, such as long QT syndrome or Brugada syndrome,” continues Dr. Aguilar.

According to Dr. Aguilar, the development of the ABBIE system was inspired to improve the Clustered Regularly Interspaced Short Palindromic Repeats (“CRISPR”)-associated 9 (simply “CRISPR-Cas9”) gene-editing technology, which improved the speed and accessibility of gene editing to a larger number of laboratories. The CRISPR-Cas9 technology has generated plenty of excitement in the scientific community, becoming the most widely used gene editing tool compared to ZFN (zinc-finger nucleases) and TALENs (transcription activator-like effector nucleases), thanks in large part to its straightforward operation, high efficiency, low cost, and simple design (https://ibn.fm/9mPjB).

As a result, new genome editing systems, which are based on the CRISPR-Cas9 technology and/or are designed to deal with the shortcomings of this technology, provide higher efficiency of DNA insertion or recombination and increased targetability. ABBIE falls in the domain of new genome editing systems that improve on the CRISPR-Cas9 yet retain the high targetability of the technology’s Cas9 proteins. For instance, ABBIE is poised to be able to edit genes of a large number of cell types at different stages of their life cycles, overcoming the limitations of current cell editing and cell engineering systems. And compared to other gene-editing technologies, ABBIE has achieved the same level of progress with much less R&D spending.

SOHM has big plans for the ABBIE platform system. According to Dr. Aguilar, ABBIE will be utilized not only for human cell therapies but also for engineering plant DNA, potentially leading to increased generation of biofuels. The system can also be commercialized as a kit for off-the-shelf utility for clients such as universities, pharmaceutical industry companies, government laboratories, and private institutions. It can also deliver genes of interest for clinical trials.

For more information, visit the company’s website at www.SOHM.com.

NOTE TO INVESTORS: The latest news and updates relating to SHMN are available in the company’s newsroom at https://ibn.fm/SHMN

• A recent Reuters report focused its attention on rare earth mining companies’ efforts to strengthen American self-sufficiency in the production of natural elements vital to modern computerized products
• Rare earth element (“REE”) enterprise Ucore Rare Metals Inc. is gaining attention as a company focused on the refining of already mined rare earths to specialize in a particular sector of the supply chain, using its proprietary RapidSX(TM) technology
• The rare earth supply chain has been a subject of concern for years because of China’s near-monopoly on mining, refining, and production, for permanent magnets, strategic because of their use in a wide variety of applications, including electric vehicles and fighter jets
• The high value placed on strengthening rare earth supply chain independence is demonstrated in the multi-million dollar award Ucore has received from the U.S. Department of Defense, accompanied by a $4.28 million award from Canada, to advance its RapidSX(TM) commercialization

A range of concerns among government leaders and industry professionals have created a high-pressure competition to develop new REE refining solutions among Western enterprises. Issues that involve REE-based products include climate change, the mining industry’s forced reliance on Chinese companies for processing rare earth elements (“REEs”) used in modern computerized products, and also resource supply chain impediments sparked by the COVID pandemic and political sea changes.

Canadian-based Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF) is at the leading edge of the race, currently in the process of developing its Louisiana facility for the commercial-scale use of its proprietary RapidSX(TM) REE high-efficiency processing technology.

As evidence of the importance that REE processing capability presents in sustaining a wide variety of large-scale goals and policies, Ucore has benefitted from millions of dollars in project funding provided this year by U.S. and Canadian national government agencies (https://ibn.fm/Y1mFK).

“The existing rare earths refining process is a nightmare. … That’s why there are so many companies promising new methods, because we need new ones,” University of Arizona mining and geological engineering professor Isabel Barton told Reuters in a recent report on the REE refining race (https://ibn.fm/ouBPC).

The report noted that Ucore initially planned to mine a rare earths deposit in Alaska, where it has an effective 100 percent ownership stake, but that Ucore “changed tack” in 2022 to focus on refining after perceiving a flaw in the West’s strategy to weaken China’s minerals dominance by trying to master both mining and refining steps simultaneously.

Others who are involved in the industry appear to be following suit in their strategies. 

“Mining companies should focus on finding new deposits,” Luisa Moreno, the president of a Canadian REE mining company, told Reuters. “You probably should let refining be handled by others that specialize in that.” The company has expressed an interest in licensing Ucore’s technology, the report notes.

Ucore has spent the last several months demonstrating the capabilities of its RapidSX(TM) REE processing technology at a facility in Ontario, where it has conducted head-to-head comparisons between RapidSX(TM) and the industry-standard for REE solvent extraction (known as CSX, or simply SX).

The company’s preparations to launch commercial-scale operations at its Louisiana Strategic Metals Complex (“SMC”) facility — building up to 7,500 metric tons of total rare earth oxide (“TREO”) production from an initial 2,000 metric tons startup — is the first of three planned SMCs in the United States and Canada.

Ucore is in talks with 17 mining companies currently to buy their lightly processed supplies of rare earths and have them shipped to the Louisiana SMC for processing and eventual production of the permanent magnets key to computerized products ranging from uses in electric vehicles to U.S. fighter jets.

China’s decision in late November requiring government approval of its companies’ high-grade graphite exports, another element of the computerized products supply chain, focused additional attention on the industry trend because of concerns about Chinese authorities’ ability to pick and choose which companies will obtain Chinese graphite if they wish (https://ibn.fm/2kM60).

For more information, visit the company’s website at www.Ucore.com.

NOTE TO INVESTORS: The latest news and updates relating to UURAF are available in the company’s newsroom at https://ibn.fm/UURAF

• SuperCom, a leading provider of traditional and digital identity solutions, is offering advanced electronic monitoring solutions to address the growing cases of domestic violence worldwide
• Considering just the United States, domestic violence is now believed to affect 3 out of 10 women and 1 in 10 men
• With its PureProtect electronic monitoring technology, SuperCom is offering law enforcement near real-time information and many lines of communication, allowing for superior victim protection with the enforcement of court restrictions

SuperCom (NASDAQ: SPCB), a global leading provider of traditional and digital identity solutions, offering advanced safety, identification, and security products and solutions to governments, is using advanced technology to reduce and prevent crime, specifically domestic violence. Through its propriety electronic monitoring (“EM”) platform, the company offers advanced EM solutions and services that have repeatedly been shown to protect domestic violence victims in multiple countries.

This comes in the wake of growing cases of domestic violence, a situation which is now encouraging governments to explore monitoring technology as a way to mitigate these cases. In England and Wales alone, a crime survey revealed that an estimated 2.1 million people aged 16 years and over experienced domestic abuse in the year ending March 2023. Police records showed a total of 889,918 domestic abuse-related crimes in the same period, a similar number to the previous year (https://ibn.fm/63hEe). In the United States, a study showed that nearly 3 in 10 women and 1 in 10 men had experienced rape, physical violence, and/or stalking by a partner, a worrying trend that calls for action sooner rather than later (https://ibn.fm/hQ328). By apprehending domestic violence offenders and then effectively monitoring them to prevent future contact with potential victims, cases of additional violence can be effectively prevented, something SuperCom’s EM technology is ideally designed to do.

In an FBI report released in 2022, it was noted that close to 600 murder-suicides occur yearly in the country, accounting for 1,000 to 1,500 deaths. Of the cases that law enforcement reports, 65% involve intimate partners, with 81% occurring in the home (https://ibn.fm/JxmPU). This is a worrying statistic, one that is further compounded by the fact that a domestic abuser is likely to abuse their partner again, even if previously incarcerated. A report showed that 10-18% of those arrested for domestic violence are arrested again in six months, while 15-30% face a second arrest within 28 months, and up to 60% are rearrested within ten years (https://ibn.fm/TP816).

To protect the victims of domestic abuse, governments are resorting to offender monitoring systems such as SuperCom’s. With its PureProtect product, the company can offer law enforcement near real-time information and many lines of communication, allowing for the enforcement of a safe distance between the offender and the victims. Its PureTag BLE bracelet with advanced tampering detection, paired with the PureMonitor software and PureProtect Smartphone, offers a life-saving domestic violence solution, allowing for victim protection and the enforcement of court restrictions (https://ibn.fm/a6i8M).

So far, several governments have adopted SuperCom’s offerings, recently including Romania and Finland. The company’s expansion into the US market promises to offer the same benefits, if not more, significantly enhancing the safety of domestic violence victims, particularly in the wake of the growing cases being reported. By doing so, the company is not only living up to its mission to revolutionize the public safety sector worldwide through proprietary electronic monitoring technology, data intelligence, and complementary services but also to create shareholder value.

For more information, visit the company’s website at www.SuperCom.com.

NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB

• SOHM, a generic drug manufacturing and distributing innovator, announced its development collaboration with the University of Arizona Center for Innovation (“UACI”) for the advancement of its ABBIE platform
• In the arrangement, SOHM will establish offices and a wet lab bench, taking advantage of UACI’s robust and specialized infrastructure
• SOHM’s management is optimistic about the collaboration and is confident that this is but the first step toward deepening new lab operations
• It also marks a significant milestone, as it anticipates monetizing ABBIE off-the-shelf, non-viral gene editing kits

SOHM (OTC: SHMN), a generic drug manufacturing and distributing innovator, just announced its development collaboration with the University of Arizona Center for Innovation (“UACI”) for the advancement of its revolutionary ABBIE platform. This marks a significant milestone for SOHM, notably as it anticipates monetizing ABBIE off-the-shelf, non-viral gene editing kits through licensing opportunities as early as 2024 (https://ibn.fm/ZM4JH).

UACI expressed optimism in the arrangement, citing their confidence in ABBIE thriving through the program.

“We are delighted to assist SOHM and the development of ABBIE technology. UACI offers comprehensive support, including SBIR grant assistance, access to core research facilities, award opportunities, and investor networking,” noted Eric Smith, UACI’s Executive Director.

“Our Good Laboratory Practice (‘GLP’) facilities provide an ideal environment for technology growth, from conceptualization to clinical application. We are confident that ABBIE will thrive through our program,” he added.

In the arrangement, SOHM will establish offices and a wet lab bench, taking advantage of UACI’s robust and specialized infrastructure and a best-practice environment with certified GLP. It is confident that going with UACI would help fast-track development, ultimately allowing it to achieve its 2024 goal of taking the technology to market.

ABBIE, SOHM’s flagship offering, is a platform for non-viral gene editing technology that enables the rapid introduction of genes of interest while offering same-day screening. Given its potential, SOHM looks to develop and deploy non-viral gene-editing kits that will be developed into cell-based therapies, biologics, and diagnostics, ultimately allowing it to tap into the global biotechnology kit market, which is estimated to post a 10.9% CAGR between 2023 and 2030.

Industry experts have lauded non-viral gene-editing platforms, noting that they are at the forefront of research and development in genetics. In addition, they have highlighted their potential to treat genetic diseases while advancing biological research. More importantly, they have noted that non-viral gene-editing methods have shown potential in eliminating concerns related to immune responses, insertional mutagenesis associated with viral vectors, safety, and efficiency, as associated with current alternatives in the market.

SOHM’s management is optimistic about the collaboration and is confident that this is the first step toward deepening new lab operations.

“Having experienced the university’s world-class research facilities firsthand, I am confident in the success of ABBIE under this collaboration,” noted Dr. David Aguilar, SOHM’s COO.

“UACI has supported the company’s development. We recognize that this relationship will only deepen with the new lab operations,” he added.

For more information, visit the company’s website at www.SOHM.com.

NOTE TO INVESTORS: The latest news and updates relating to SHMN are available in the company’s newsroom at https://ibn.fm/SHMN